Nasdaq:EQ
Equillium, Inc.
A specialized biopharmaceutical firm utilizing a proprietary platform to develop novel therapeutics for oncology and rare disease indications.
Key Metrics
Investment Thesis
Bull Case
Equillium offers high-risk/high-reward potential if its proprietary platform successfully delivers novel assets with blockbuster commercial profiles in oncology and rare diseases. The company has demonstrated a trend toward improving financial efficiency by narrowing its net loss year-over-year while growing revenue. A successful licensing deal or partnership could provide immediate cash infusion to extend the runway beyond current cash reserves of $18.1M.
Bear Case
The company's continuous negative net income and negative operating cash flow raise serious concerns about its ability to sustain operations without further dilution or external funding. With a retained earnings deficit exceeding $193M and no accounts receivable, the business model appears fragile and potentially reliant on non-recurring transactions. The lack of diversified revenue streams and heavy dependence on specific drug candidates exposes investors to extreme binary outcomes upon product approval.
About Equillium, Inc.
Equillium Inc. (EQ) is a specialty pharmaceutical company focused on the discovery and development of novel medicines, primarily within oncology and rare diseases. The company leverages its proprietary technology platform to address unmet medical needs in complex therapeutic areas across global markets.
Analysis
Management Discussion
While revenue increased to $41.1M in 2024 from $36.1M the prior year, the company continues to report significant net losses, with operating profit declining to -$8.3M. Cash flow from operations turned negative at -$19.0M, yet cash flow from investing was positive due to a non-operating inflow of $13.8M, likely reflecting asset sales or licensing deals rather than organic growth. The company managed to reduce its net loss year-over-year from -$13.3M in 2023 to -$8.1M in 2024, showing some progress in expense management despite ongoing operational challenges.
Industry Overview
The specialty pharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory scrutiny before products can reach market. Companies in this sector often operate with thin margins until a blockbuster drug launches, relying heavily on intellectual property protection and strategic partnerships. Success depends on the ability to navigate complex clinical trials and secure favorable pricing negotiations in competitive oncology markets.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $15.8M | $36.1M | $41.1M |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $15.8M | $36.1M | $41.1M |
| Operating Expenses | $77.8M | $50.6M | $49.4M |
| Operating Income | $-62.1M | $-14.5M | $-8.3M |
| R&D | $37.5M | $37.0M | — |
| G&A | $17.2M | $13.6M | $11.9M |
| Stock-Based Comp | $4.8M | $4.0M | $3.8M |
| D&A | $118.0K | — | — |
| Depreciation | $118.0K | $126.0K | $137.0K |
| Other OpEx | $23.0M | $0 | $37.4M |
| Non-Operating Income | $-352.0K | $1.8M | $563.0K |
| Interest Income | $420.0K | $2.3M | $1.4M |
| Pre-Tax Income | $-62.4M | $-12.8M | $-7.7M |
| Income Tax | $0 | $580.0K | $361.0K |
| Continuing Ops | $-62.4M | $-13.3M | $-8.1M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-62.4M | $-13.3M | $-8.1M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-62.4M | $-13.3M | $-8.1M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $76.7M | $49.3M | $25.0M |
| Cash & Equivalents | $59.1M | $23.2M | $18.1M |
| Accounts Receivable | $2.8M | $3.7M | $0 |
| Prepaid Expenses | $2.9M | $4.7M | $2.4M |
| Other Current Assets | $11.9M | $17.6M | $4.5M |
| Long-Term Assets | $1.7M | $1.2M | $626.0K |
| PP&E (Net) | $391.0K | $315.0K | $262.0K |
| Operating Leases | $1.2M | $796.0K | $364.0K |
| Other LT Assets | $104.0K | $70.0K | $0 |
| Total Assets | $78.4M | $50.5M | $25.6M |
| Current Liabilities | $32.0M | $27.6M | $6.4M |
| Accounts Payable | $4.0M | $4.7M | $2.7M |
| Current Debt | $5.7M | — | — |
| Current Leases | $408.0K | $440.0K | $197.0K |
| Other Current Liab | $14.7M | $15.7M | $0 |
| Long-Term Liabilities | $14.4M | $384.0K | $187.0K |
| Long-Term Debt | $3.2M | — | — |
| LT Operating Leases | $824.0K | $384.0K | $187.0K |
| Other LT Liab | $10.4M | $0 | $0 |
| Total Liabilities | $46.5M | $28.0M | $6.5M |
| Shareholders' Equity | $31.9M | $22.6M | $19.1M |
| Retained Earnings | $-172.4M | $-185.7M | $-193.8M |
| AOCI | $76.0K | $140.0K | $781.0K |
| Total L&E | $78.4M | $50.5M | $25.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-62.4M | $-13.3M | $-8.1M |
| Non-Cash Adjustments | $22.7M | $-2.0M | $15.9M |
| Working Capital Changes | $31.0M | $-6.5M | $-26.9M |
| Cash from Operations | $-8.7M | $-21.8M | $-19.0M |
| Capital Expenditures | $279.0K | $50.0K | $85.0K |
| Cash from Investing | $18.7M | $-4.8M | $13.8M |
| Share Buybacks | — | $260.0K | — |
| Cash from Financing | $-1.2M | $-9.2M | $164.0K |
| FX Effect | $5.0K | $-118.0K | $-83.0K |
| Net Change in Cash | $8.7M | $-35.9M | $-5.1M |
| Beginning Cash | $50.4M | $59.1M | $23.2M |
| Ending Cash | $59.1M | $23.2M | $18.1M |
Frequently Asked Questions
How does Equillium, Inc. make money?
The company's revenue is driven by the commercialization of its core proprietary assets, specifically targeting oncology indications and other high-value therapeutic areas such as rare diseases. Financials indicate a reliance on specific product launches and potential licensing arrangements rather than diversified segment reporting.
What are the main risks for EQ?
The company faces significant clinical and commercial risk as its revenue growth is heavily dependent on the successful approval and market adoption of specific drug candidates. Significant operating losses and a substantial retained earnings deficit indicate high burn rates that could deplete cash reserves if future financing is not secured. Regulatory hurdles in oncology and rare diseases remain a critical uncertainty that could delay or prevent product launches. The absence of accounts receivable suggests potential revenue recognition issues or a business model reliant on upfront payments rather than recurring sales.
What is EQ's competitive advantage?
Equillium possesses a unique proprietary platform technology that enables the rapid identification and development of novel drug candidates with distinct mechanisms of action. The company benefits from a streamlined R&D approach that reduces time-to-market compared to traditional large-cap biopharma models. Its focus on niche, high-need areas like rare diseases provides first-mover potential in less crowded therapeutic landscapes.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.